Literature DB >> 9701421

Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer.

G Luporini1, S Barni, E Marchi, L Daffonchio.   

Abstract

Nonproductive cough is a frequent and distressing symptom in patients with lung cancer, and it is not even relieved by palliative chemotherapy. A double-blind, randomized clinical trial regarding the treatment of nonproductive cough was performed in 140 adults with primary lung cancer or metastatic cancer of the lungs. The therapeutic efficacy and the tolerability of a 7-day treatment with levodropropizine drops (75 mg t.i.d.) were evaluated in comparison with dihydrocodeine drops (10 mg t.i.d.; 7 days). Efficacy was assessed on the basis of cough severity scores, number of night awakenings due to cough, and overall estimate of antitussive efficacy. Tolerability was evaluated by laboratory results, vital signs and any adverse event occurring during the clinical trial, including presence or absence of somnolence. Subjective cough severity was significantly reduced during treatment with either levodropropizine and dihydrocodeine, the antitussive effect and its time-profile being similar for both drugs. Also, according to the investigator's evaluation, both levodropropizine and dihydrocodeine produced a significant decrease in cough severity. Concurrently with the relief of cough, the number of night awakenings was decreased significantly by both drugs, with no difference between the two treatments. No change in laboratory test values was considered clinically relevant, and vital signs were not clinically affected. The number of patients reporting adverse events was similar in the levodropropizine (n=6) and dihydrocodeine (n=4) group. However, the percentage of patients experiencing somnolence in the group receiving levodropropizine (8%) was significantly lower as compared with that of the dihydrocodeine group (22%). These results confirm the antitussive effectiveness of levodropropizine and suggest a more favourable benefit/risk profile when compared to dihydrocodeine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701421     DOI: 10.1183/09031936.98.12010097

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  [Good sense and nonsense of antitussive agents].

Authors:  A Gillissen; S Tasci; S Ewig; H Schäfer; S Zielen
Journal:  Internist (Berl)       Date:  2001-01       Impact factor: 0.743

Review 2.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

Authors:  Donald C Bolser
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

3.  Interventions for cough in cancer.

Authors:  Alex Molassiotis; Chris Bailey; Ann Caress; Jing-Yu Tan
Journal:  Cochrane Database Syst Rev       Date:  2015-05-19

4.  A case of immunoglobulin E mediated anaphylaxis to levodropropizine.

Authors:  Kyung Hee Park; Il Seon Yun; Soo-Young Choi; Jae-Hyun Lee; Chein-Soo Hong; Jung-Won Park
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

5.  RSD931, a novel anti-tussive agent acting on airway sensory nerves.

Authors:  J J Adcock; G J Douglas; M Garabette; M Gascoigne; G Beatch; M Walker; C P Page
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

6.  Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study.

Authors:  B Frank; M G Serpell; J Hughes; J N S Matthews; D Kapur
Journal:  BMJ       Date:  2008-01-08

7.  Cough management: a practical approach.

Authors:  Francesco De Blasio; Johann C Virchow; Mario Polverino; Alessandro Zanasi; Panagiotis K Behrakis; Gunsely Kilinç; Rossella Balsamo; Gianluca De Danieli; Luigi Lanata
Journal:  Cough       Date:  2011-10-10

8.  Levodropropizine for treating cough in adult and children: a meta-analysis of published studies.

Authors:  Alessandro Zanasi; Luigi Lanata; Giovanni Fontana; Federico Saibene; Peter Dicpinigaitis; Francesco De Blasio
Journal:  Multidiscip Respir Med       Date:  2015-05-31

9.  Levodropropizine-Induced Anaphylaxis: Case Series and Literature Review.

Authors:  Jae Won Song; Young Sook Jang; Moon Chan Jung; Joo Hee Kim; Jeong Hee Choi; Sunghoon Park; Yong Il Hwang; Seung Hun Jang; Ki Suck Jung
Journal:  Allergy Asthma Immunol Res       Date:  2017-05       Impact factor: 5.764

10.  Physician-Perceived Predictive Factors for the Effectiveness of Drugs for Treating Cancer Dyspnea: Results of a Nationwide Survey of Japanese Palliative Care Physicians.

Authors:  Yoshinobu Matsuda; Ryo Matsunuma; Kozue Suzuki; Masanori Mori; Hiroaki Watanabe; Takashi Yamaguchi
Journal:  Palliat Med Rep       Date:  2020-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.